Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

Afatinib

Rating: Māhele:

ʻO ka pauma Afatinib, kūʻai ʻia ma lalo o ka inoa ʻo Gilotrif i waena o nā mea ʻē aʻe, kahi lāʻau i hoʻohana ʻia e mālama ai i ka maʻi liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC).

Product Description

Nā ʻano kikoʻī

Product Name Pauka Afatinib
Kāleka CAS 439081-18-2
Ka Lā Molecular C24H25ClFN5O3
Kaumaha Kaumaha 485.9
'O Synonyms Pauma Afatinib;

439081-18-2;

850140-72-6;

BIBW2992;

ʻO Tovok.

Keʻano ʻO kaʻeleʻele'alaʻula
Ka mālama a me ka lima lima E mālama iā ia i ka mahana wela a mamao aku mai ka wela a me ka momona.

 

Hōʻike Powder Afatinib

ʻO ka pauma Afatinib, kūʻai ʻia ma lalo o ka inoa ʻo Gilotrif i waena o nā mea ʻē aʻe, kahi lāʻau i hoʻohana ʻia e mālama ai i ka maʻi liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC).

Hoʻohana nui ʻia ka paukū ʻo Afatinib e mālama i nā hihia o NSCLC e mālama i nā hoʻololi i ka ʻenemi ulu ulu epidermal (EGFR) ʻāpana.

 

ʻO Afatinib Powder Mekanika o ka Hana

E like me ka lapatinib a me ka neratinib, ʻo ka paukū afatinib kahi mea hoʻopōpō kinase protein i hiki ʻole hoʻi ke kāohi i ka mea ulu ulu epidermal kanaka 2 (Her2) a me nā ʻepekema ulu ulu epidermal (EGFR) kinases. ʻAʻole hana wale ka paukū Afatinib e kūʻē i nā hoʻololi EGFR i hoʻokumu ʻia e nā mea hanauna mua tyrosine-kinase (TKI) e like me erlotinib a i ʻole gefitinib, akā e kūʻē pū ana hoʻi i nā loli liʻiliʻi i kū ʻole i kēia mau lāʻau. Eia nō naʻe, ʻaʻole ʻeleu ia e kūʻē i ka mutation T790M e koi pinepine ai i nā lāʻau ʻekolu e like me osimertinib. Ma muli o kāna hana ʻē aʻe e kūʻē iā Her2, ʻimi ʻia nei no ka maʻi ʻaʻai umauma a me nā maʻi ʻino ʻē aʻe EGFR a me Her2.

 

Noi Afatinib Powder

Ua loaʻa i ka paukū ʻo Afatinib ka ʻae hoʻomalu no ka hoʻohana ʻana ma ke ʻano he lapaʻau no ka maʻi ʻaʻai liʻiliʻi liʻiliʻi ʻole, ʻoiai aia he hōʻike e kū ana e kākoʻo i kāna hoʻohana ʻana i nā maʻi ʻē aʻe e like me ka maʻi ʻaʻai umauma.

 

Nā hopena ʻaoʻao ʻo Afatinib Powder & Warning

Kaulana loa (> 10% alapine)

▪ Diarrhea (> 90%)

▪ Huehue / dermatitis huehue

▪ Stomatitis

▪ Paronychia

▪ Hoʻoemi i ka makemake

▪ Koko ihu

▪ Ka ʻumeʻume

▪ ʻili maloʻo

 

Common (1-10% alapine (frequency))

▪ Hoʻoholo wai, Hoʻololi ka ʻono, Maka maloʻo

▪ Cystitis, Cheilitis, Fiva

▪ Ka ihu ihu

▪ Ka liʻiliʻi o ka potassium i loko o ke koko

▪ Conjunctivitis

▪ Hoʻonui ALT

▪ Hoʻonui AST

▪ Ka maʻi wawae lima

▪ Pākuʻi kaʻiʻo

▪ Ka hōʻino ʻana o ka hakuʻala a me / a i ʻole kūleʻa

 

Kaulana (0.1-1% alapine)

▪ Keratitis

▪ maʻi ma waena

 

Reference

[1] "Gilotrif (afatinib pauka) papa, kiʻi ʻoniʻoni i uhi ʻia". DailyMed. Boehringer Ingelheim Pharmaceuticals, Inc. 18 ʻOkakopa 2019. Ua kiʻi ʻia 4 Nowemapa 2020.

[2] Spreitzer H (13 Mei 2008). "Neue Wirkstoffe - Tovok". Österreichische Apothekerzeitung (i Kelemania) (10/2008): 498

[3] Minkovsky N, Berezov A (Kekemapa 2008). "BIBW-2992, kahi pālua receptor tyrosine kinase inhibitor no ka mālama ʻana i nā tumors paʻa". ʻO ka manaʻo o kēia manawa i nā lāʻau lapaʻau noiʻi. 9 (12): 1336–46. PMID 19037840.

[4] “Afatinib Powder”. US Food and Drug Administration. 12 July 2013.[dead link] [5] “Giotrif Afatinib Powder (as afatinib dimaleate)” (PDF). TGA eBusiness Services. Boehringer Ingelheim Pty Limited. 7 November 2013. Retrieved 28 January 2014.

[6] Vavalà T (2017). "Ke kuleana o ka pauma afatinib i ka mālama ʻana i ka carcinoma cell squamous cell holomua". ʻOihana Pharmacology. 9: 147-157. hana: 10.2147 / CPAA.S112715. PMC 5709991. PMID 29225480.


  • ʻO DacomitinibFree heluhelu hou
  • ʻO GefitinibFree heluhelu hou
  • AZD 3759Free heluhelu hou